YAP1 and neoplasm: Overall, multiple mechanisms of Hippo pathway dysregulation have been described in chronic inflammation and fibrosis preceding liver carcinogenesis, providing the rationale for exploring YAP/TAZ targeting as a tumor-preventing strategy.